imantsu/E+ via Getty Images I highlighted my ‘Buy’ thesis on IDEX’s (NYSE:IEX) in my previous article published in June 2024, arguing the moderation of order growth. IDEX released its Q2 result on July 31, reporting a 4% decline in organic revenue and lowering the full-year growth guidance due to project delays and overall softness in the industrial market. Despite these near-term headwinds, I favor IDEX’s efforts in portfolio management and capital allocation. I reiterate 'Buy' rating with a fair price ...